Search Results - "GOLAS, Jonathan"

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1) by Sung, Matthew, Tan, Xingzhi, Lu, Bingwen, Golas, Jonathan, Hosselet, Christine, Wang, Fang, Tylaska, Laurie, King, Lindsay, Zhou, Dahui, Dushin, Russell, Myers, Jeremy S, Rosfjord, Edward, Lucas, Judy, Gerber, Hans-Peter, Loganzo, Frank

“…Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) that has demonstrated clinical benefit for patients with HER2 metastatic breast cancer;…”
Get full text

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase by RABINDRAN, Sridhar K, DISCAFANI, Carolyn M, REICH, Marvin F, RU SHEN, XIAOQING SHI, TSOU, Hwei-Ru, WANG, Yu-Fen, WISSNER, Allan, ROSFJORD, Edward C, BAXTER, Michelle, FLOYD, M. Brawner, GOLAS, Jonathan, HALLETT, William A, JOHNSON, Bernard D, NILAKANTAN, Ramaswamy, OVERBEEK, Elsebe

“…HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers. Overexpression of HER-2 is seen in 25-30% of…”
Get full text

Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity by Tsou, Hwei-Ru, Overbeek-Klumpers, Elsebe G, Hallett, William A, Reich, Marvin F, Floyd, M. Brawner, Johnson, Bernard D, Michalak, Ronald S, Nilakantan, Ramaswamy, Discafani, Carolyn, Golas, Jonathan, Rabindran, Sridhar K, Shen, Ru, Shi, Xiaoqing, Wang, Yu-Fen, Upeslacis, Janis, Wissner, Allan

“…A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitrile derivatives that function as irreversible inhibitors of human epidermal growth factor…”
Get full text

Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors by Ji, Changhua, Roy, Marc D, Golas, Jonathan, Vitsky, Allison, Ram, Sripad, Kumpf, Steven W, Martin, Matthew, Barletta, Frank, Meier, William A, Hooper, Andrea T, Sapra, Puja, Khan, Nasir K, Finkelstein, Martin, Guffroy, Magali, Buetow, Bernard S

“…Immune checkpoint inhibitors (ICI) targeting PD1, PDL1, or CTLA4 are associated with immune-related adverse events (irAE) in multiple organ systems including…”
Get full text

Abstract 4549: Evaluation of GUCY2c-CD3 bispecific targeting GI cancers in an orthotopic colorectal tumor model by Yao, Johnny, Mathur, Divya, Yang, Sharon, Conant, Roger, Kearney, Jessica, Buklan, Vlad, Golas, Jonathan, Rosfjord, Edward

“…Abstract GUCY2c is a tumor target expressed in >90% of colorectal cancer (CRC). It is also expressed on the apical side of intestinal epithelial tight…”
Get full text

Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma by Molina-Sánchez, Pedro, Ruiz de Galarreta, Marina, Yao, Melissa A., Lindblad, Katherine E., Bresnahan, Erin, Bitterman, Elizabeth, Martin, Tiphaine C., Rubenstein, Troy, Nie, Kai, Golas, Jonathan, Choudhary, Shambhunath, Bárcena-Varela, Marina, Elmas, Abdulkadir, Miguela, Veronica, Ding, Ying, Kan, Zhengyan, Grinspan, Lauren Tal, Huang, Kuan-Lin, Parsons, Ramon E., Shields, David J., Rollins, Robert A., Lujambio, Amaia

“…The pattern of genetic alterations in cancer driver genes in patients with hepatocellular carcinoma (HCC) is highly diverse, which partially explains the low…”
Get full text

A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers by Mathur, Divya, Root, Adam R, Bugaj-Gaweda, Bozena, Bisulco, Stephanie, Tan, Xingzhi, Fang, Wei, Kearney, Jessica C, Lucas, Justin, Guffroy, Magali, Golas, Jonathan, Rohde, Cynthia M, Stevens, Chad, Kamperschroer, Cris, Kelleher, Kerry, Lawrence-Henderson, Rosemary F, Upeslacis, Erik, Yao, Johnny, Narula, Jatin, LaVallie, Edward R, Fernandez, Diane R, Buetow, Bernard S, Rosfjord, Edward, Bloom, Laird, King, Lindsay E, Tchistiakova, Lioudmila, Nguyen, Anhco, Sapra, Puja

“…Gastrointestinal cancers remain areas of high unmet need despite advances in targeted and immunotherapies. Here, we demonstrate potent, tumor-selective…”
Get full text

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice by Fisher, Timothy S., Hooper, Andrea T., Lucas, Justin, Clark, Tracey H., Rohner, Allison K., Peano, Bryan, Elliott, Mark W., Tsaparikos, Konstantinos, Wang, Hui, Golas, Jonathan, Gavriil, Maria, Haddish-Berhane, Nahor, Tchistiakova, Lioudmila, Gerber, Hans-Peter, Root, Adam R., May, Chad

“…Strong evidence exists supporting the important role T cells play in the immune response against tumors. Still, the ability to initiate tumor-specific immune…”
Get full text

Abstract 2861: Dose-dependent tissue distribution and tumor targeting of Notch3-ADC using fluorescence molecular tomography imaging by Giddabasappa, Anand, Gupta, Parul, Leal, Mauricio, Golas, Jonathan, Li, Fengping, Yang, Bing, Esparza, Antonio, Winkelmann, Christopher, Geles, Kenneth

“…Abstract Background: NOTCH3, a cell surface receptor involved in cell-cell communications, is over-expressed or amplified in certain human tumors. NOTCH3 is…”
Get full text

Abstract 2283: A novel GUCY2C - CD3 bispecific engages T cells to induce cytotoxicity in gastrointestinal tumors by Mathur, Divya, Root, Adam, Bugaj-Gaweda, Bozena, Tan, Xingzhi, Fang, Wei, Bisulco, Stephanie, Golas, Jonathan, Fernandez, Diane, Kearney, Jessica, Upeslacis, Eric, Yao, Johnny, Rosfjord, Edward, Stevens, Chad, Kobylarz, Keith, King, Lindsay, Narula, Jatin, Kelleher, Kerry, Schaer, David, Kamperschroer, Cris, Buetow, Bernard, Rohde, Cynthia, Moreau, Allison, Wong, Gilbert, Sapra, Puja

“…Abstract Gastrointestinal malignancies, including colorectal cancer (CRC) remain an area of high unmet need. Here we demonstrate tumor selective and potent in…”
Get full text

Cooperation between distinct cancer driver genes underlies inter-tumor heterogeneity in hepatocellular carcinoma by Molina-Sánchez, Pedro, de Galarreta, Marina Ruiz, Yao, Melissa A., Lindblad, Katherine E., Bresnahan, Erin, Bitterman, Elizabeth, Martin, Tiphaine C., Rubenstein, Troy, Nie, Kai, Golas, Jonathan, Choudhary, Shambhunath, Bárcena-Varela, Marina, Elmas, Abdulkadir, Miguela, Veronica, Ding, Ying, Kan, Zhengyan, Grinspan, Lauren Tal, Huang, Kuan-Lin, Parsons, Ramon E., Shields, David J., Rollins, Robert A., Lujambio, Amaia

“…This novel collection of murine hepatocellular carcinoma models and corresponding cell lines establishes the role of cancer driver genes in promoting…”
Get full text

Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy by Maresca, Kevin P., Chen, Jianqing, Mathur, Divya, Giddabasappa, Anand, Root, Adam, Narula, Jatin, King, Lindsay, Schaer, David, Golas, Jonathan, Kobylarz, Keith, Rosfjord, Edward, Keliher, Edmund, Chen, Laigao, Ram, Sripad, Pickering, Eve H., Hardwick, James S., Rejto, Paul A., Hussein, Amira, Ilovich, Ohad, Staton, Kevin, Wilson, Ian, McCarthy, Timothy J.

“…Purpose A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of…”
Get full text

Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth by Barsotti, Anthony M, Ryskin, Michael, Zhong, Wenyan, Zhang, Wei-Guo, Giannakou, Andreas, Loreth, Christine, Diesl, Veronica, Follettie, Maximillian, Golas, Jonathon, Lee, Michelle, Nichols, Timothy, Fan, Conglin, Li, Gang, Dann, Stephen, Fantin, Valeria R, Arndt, Kim, Verhelle, Dominique, Rollins, Robert A

“…In addition to genetic alterations, cancer cells are characterized by myriad epigenetic changes. EZH2 is a histone methyltransferase that is over-expressed and…”
Get full text

SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models by GALAS, Jennifer M, LUCAS, Judy, FANGBIAO LI, TITSCH, Craig, HUSELTON, Christine, CHAUDHARY, Inder, BOSCHELLI, Frank, ETIENNE, Carlo, GOLAS, Jonathan, DISCAFANI, Carolyn, SRIDHARAN, Latha, BOGHAERT, Erwin, ARNDT, Kim, FEI YE, BOSCHELLI, Diane H

“…Src up-regulation is a common event in human cancers. In colorectal cancer, increased Src levels are an indicator of poor prognosis, and progression to…”
Get full text

Abstract 1697: Therapeutic targeting the NOTCH3 receptor with antibody drug conjugates by Geles, Kenneth G., Gao, Yijie, Sridharan, Latha, Giannakou, Andreas, Yamin, Ting-Ting, Golas, Jonathan, Lucas, Judy, Charati, Manoj, Li, Xiantang, Guffroy, Magali, Nichols, Tim, Wang, Kai, Follettie, Max, Maderna, Andreas, Tchistiakova, Lioudmila, Gerber, Hans-Peter, Sapra, Puja

“…Abstract Activation and mutation of the NOTCH signaling pathway is oncogenic in many tissue types and the target of multiple anti-cancer therapies currently in…”
Get full text

Preclinical Evaluation of 89 Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy by Maresca, Kevin P, Chen, Jianqing, Mathur, Divya, Giddabasappa, Anand, Root, Adam, Narula, Jatin, King, Lindsay, Schaer, David, Golas, Jonathan, Kobylarz, Keith, Rosfjord, Edward, Keliher, Edmund, Chen, Laigao, Ram, Sripad, Pickering, Eve H, Hardwick, James S, Rejto, Paul A, Hussein, Amira, Ilovich, Ohad, Staton, Kevin, Wilson, Ian, McCarthy, Timothy J

“…A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of…”
Get full text

Abstract 2476: Bispecific redirected T-cell immunotherapy targeting P-cadherin expressing tumors by Fisher, Timothy S., Root, Adam, Peano, Bryan, Rohner, Allison, Lucas, Justin, Elliott, Mark, Tsaparikos, Konstantinos, Wang, Hui, Golas, Jonathan, Gavriil, Maria, Benard, Susan, He, Tao, Clark, Tracey, Haddish-Berhane, Nahor, Alderson, Ralph, Yang, Yinhua, Johnson, Syd, Moore, Paul, Tchistiakova, Lioudmila, Gerber, Hans-Peter, May, Chad

“…Abstract Introduction: Strong evidence exists supporting the important role T-cells play in the immune response against tumors. Still, the ability to initiate…”
Get full text

Abstract 5471: Notch-antibody drug conjugates have a different mechanism of action than Notch signaling inhibitors and induce tumor regression by Geles, Kenneth G., Gao, Yijie, Sridharan, Latha, Giannakou, Andreas, Yamin, Ting-Ting, Golas, Jonathan, Charati, Manoj, Khandke, Kiran, Lucas, Judy, Maderna, Andreas, O'Donnell, Christopher J., Tchistiakova, Lioudmila, Gerber, Hans-Peter, Sapra, Puja

“…Abstract There are four different Notch receptors in mammalian cells that have overlapping patterns of expression in embryonic and adult tissues, but fulfill…”
Get full text